Cardiol Therapeutics (TSE:CRDL) Releases Earnings Results

Cardiol Therapeutics (TSE:CRDL) issued its earnings results on Wednesday. The company reported C($0.05) earnings per share for the quarter, FiscalAI reports.

Cardiol Therapeutics Trading Up 0.5%

Shares of TSE:CRDL traded up C$0.01 during trading on Wednesday, reaching C$2.12. 236,815 shares of the company traded hands, compared to its average volume of 100,563. The firm has a market capitalization of C$244.38 million, a price-to-earnings ratio of -5.44 and a beta of 0.27. Cardiol Therapeutics has a 52-week low of C$1.23 and a 52-week high of C$2.33. The company has a current ratio of 4.39, a quick ratio of 6.84 and a debt-to-equity ratio of 0.48. The business’s fifty day moving average is C$1.62 and its 200-day moving average is C$1.62.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.